Create a free account or log in.
BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including cancer and severe respiratory infections.
AXL: a promising target to treat life-threatening diseases
The tyrosine kinase target AXL is known to play an important role in both the innate and adaptive immune systems, BerGenBio is developing two highly selective AXL inhibitors bemcentinib and tilvestamab.
Business model: R&D excellence and strategic partnerships
BerGenBio is leveraging its solid leadership position in understanding the role of AXL and related kinase signalling in diseases of high unmet need to develop a diversified pipeline of selective AXL inhibitors.
Worldwide
Create a free account or log in to add companies to your watchlist, access more data, and chat directly with filings using our AI assistant (as shown!).
| Filing Information | Date & Language | Document Details | Actions |
|---|
No filings found matching your criteria
213800TYYFXKYF3V2A23
IKM
Sector
Health Care
Country
Spain
ISIN
Founded
1NKEMIA specializes in biotechnology research and innovation, offering advanced solutions for the pharmaceutical, chemical, and energy sectors.
2CUREX
Sector
Health Care
Country
Sweden
ISIN
SE0010468124
Founded
2cureX AB is a Danish biotech company specializing in functional precision medicine. It develops diagnostic tools to personalize cancer treatment.
VSC
Sector
Health Care
Country
Germany
ISIN
DE000A3E5C40
Founded
1997
4SC focuses on the development of novel small molecule drugs that target key mechanisms of cancer development, such as histone …
ABERA
Sector
Health Care
Country
Sweden
ISIN
SE0015245097
Founded
Abera Bioscience is active in biotechnology. The company specializes in the development of vaccines based on its own internal developed …
ABNX
Sector
Health Care
Country
France
ISIN
FR0012616852
Founded
ABIONYX Pharma is a new-generation biotech company that aims to contribute to health through innovative therapies in indications where there …
ABLI
Sector
Health Care
Country
Sweden
ISIN
SE0002575340
Founded
2000
Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when …